13 May 2024
New poster!
New CellKeep™ poster revealed at New Frontiers in Liquid Biopsies: Data, Technology and Translational Potential on May 13th and 14th on board 034.
Discover more
9 May 2024
Come see us at ESMO Breast Cancer Congress
From May 15-17 at booth 28, where we will be showcasing our Parsortix® technology and new Portrait®+ CTC staining kit*.
Discover more
3 May 2024
New Androgen Receptor assay now in development
A new agreement with a major global pharmaceutical company to develop a Parsortix® CTC based Androgen Receptor (AR) assay for use in prostate cancer studies.
Discover more
25 April 2024
Come see us at the 4th Clinical Biomarkers & Clinical Diagnostics Europe
Visit our booth to learn how we offer a bespoke service with molecular and imaging CTC assays customised to your requirements.
Discover more
24 April 2024
Novel methodology for CTC micronuclei detection
Working in partnership with a major global biopharmaceutical provider, we will be tailoring our existing Parsortix-based DNA damage response (DDR) assay for use in pharmaceutical...
Discover more
12 April 2024
Come see us at AACR 2024
On booth 3054 where we’ll be showcasing our Parsortix® technology and new Portrait®+ CTC staining kits at the San Diego Convention Centre.
Discover more
22 March 2024
New poster!
Precision Medicine Poster Session at EBCC where we have two posters on display at poster board PB-117 & PB-123.
Discover more
20 March 2024
Portrait®+ CTC Staining Kits Now Available
We are excited to share that our first lot of Portrait+ CTC Staining Kits are packed and ready to go out to our customers.
Discover more
7 March 2024
Come see us at the Next-Gen Immuno-Oncology Conference
Anne-Sophie Pailhes-Jimenez, Senior Director, Head of R&D talks at 10:00-10:30 discussing PD-L1 expression in cancer cells from metastatic cancer patients.
Discover more
29 February 2024
Come see us at the 8th Liquid Biopsy for Precision Oncology Summit
Connect with us to learn about the power of Parsortix® technology and our clinical laboratory and to discover how we can support your clinical studies.
Discover more
22 February 2024
Company Team Building Day
It is great to have so many of our friends and colleagues together to strengthen inter-department relationships.
Discover more
16 February 2024
Celebrating International Women of Science
We are proud to highlight the contributions of female scientists in our team and embrace the milestones reached by women in STEM all over the...
Discover more
New service offering!
Portrait® Flex takes circulating tumor cell (CTC) analysis to the next level.
Discover more
6 February 2024
New service offering!
ANGLE’s Portrait® PD-L1 testing solution is a novel approach for evaluating the expression of PD-L1 on circulating tumour cells (CTCs).
Discover more
30 January 2024
Come see us at the 7th Annual DDR Inhibitors Summit
From Jan 30-Feb 1 at The Colonnade in Boston!
Discover more
22 January 2024
New publication!
Complementary insights from a single blood sample utilising the Parsortix® system.
Discover more
17 January 2024
New publication!
Circulating tumor cells (CTCs) harvested using the Parsortix® system, reveal a gene expression profile associated with development and progression of brain metastasis in melanoma.
Discover more
4 January 2024
Potential to transform cancer care
Molecular profiling of CTC-DNA, from CTCs enriched by Parsortix® technology, alongside ctDNA from the same blood sample has the potential to revolutionize cancer treatment.
Discover more
11 December 2023
Come see us at SABCS 2023
Where we will be discussing how liquid biopsy and the illuminating power of circulating tumor cells (CTCs) could revolutionize the treatment of breast cancer.
Discover more
4 December 2023
New product launch!
This innovative new product provides advanced immunofluorescent staining of circulating tumour cells (CTCs) enriched from blood processed by Parsortix® technology.
Discover more
17 November 2023
ANGLE Supports Children In Need 2023
Our team decided to have a fun head-to-head bake-off competition and raised a wonderful £53 for the cause!
Discover more
25 October 2023
New publication!
Research demonstrates the potential of the Parsortix® system to support powerful characterisation of CTCs in head and neck cancer.
Discover more
20 September 2023
Come see us at the 6th ACTC meeting 2023
Visit us to experience the power of the Parsortix® PC1 system, our unique FDA cleared, and CE marked circulating tumor cell (CTC) enrichment technology.
Discover more
29 June 2023
Why CTCs and liquid biopsies could one day revolutionise NHS cancer care
The article is part of the Supporting the NHS Campaign 2023 and focuses on how new innovations could improve patient outcomes and support the NHS.
Discover more
